Sergio Calvo, general manager of theranostics at GE HealthCare, joins MobiHealthNews to discuss how combining molecular ...

Molecular Partners (NASDAQ:MOLN) hosted a webcast to discuss clinical imaging and dosimetry data for MP0712, its ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing ...

Pentixafor PET/CT was well tolerated and demonstrated high specificity and moderate sensitivity for identifying unilateral ...

A study in Nature Cardiovascular Research by researchers at Washington University School of Medicine in St. Louis explores a new, noninvasive imaging technique that helps scientists visualize immune ...

Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...

Radiopharmaceutical therapy and molecular imaging—together known as Theranostics—are gaining significant traction worldwide. Even though Theranostics dates back to the early 1940s, a rapid expansion ...

Transitioning molecular imaging from a preclinical technique to a standard clinical tool could help detect the very earliest stages of disease, reports Tami Freeman Tools of the trade Left: this ...

A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter, ...